
=> d his

(FILE 'HOME' ENTERED AT 11:21:15 ON 12 OCT 2010)

```
FILE 'REGISTRY' ENTERED AT 11:21:23 ON 12 OCT 2010
L1
                STRUCTURE UPLOADED
L2
              1 S L1
L3
                STRUCTURE UPLOADED
L4
             1 S L3
L5
             20 S L3 SSS FUL
L6
             18 S L5 AND CAPLUS/LC
L7
              2 S L5 NOT L6
     FILE 'CAPLUS' ENTERED AT 11:33:04 ON 12 OCT 2010
L8
             10 S L5
L9
             7 S L8 NOT (2010/SO OR 2009/SO OR 2008/SO OR 2007/SO OR 2006/SO O
=> d 13
L3 HAS NO ANSWERS
L3
                STR
```



Structure attributes must be viewed using STN Express query preparation.

=> d ibib abs hitstr total

INVENTOR(S):

ANSWER 1 OF 7 CAPLUS COPYRIGHT 2010 ACS on STN L9

ACCESSION NUMBER: 2008:706957 CAPLUS

DOCUMENT NUMBER: 149:54020

TITLE: Bisbenzamidines and bisbenzamidoximes as parasiticides

and their preparation, pharmaceutical compositions and use in the treatment of human african trypanosomiasis Huang, Tien L.; Vanden Eynde, Jean-Jacques; Mayence,

Annie; Bacchi, Cyrus; Donkor, Isaac O.; Kode,

Nageswara

Xavier University of Louisiana, USA PATENT ASSIGNEE(S):

SOURCE: PCT Int. Appl., 60 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT N		KINI)	DATE		APPLICATION NO.						DATE			
WO 20080 WO 20080						WO 2007-US86773									
₩:	AE, AG, CH, CN, GB, GD, KM, KN, MG, MK, PI, RO, TR, TT,	AL, CO, GE, KP, MN, RS, TZ,	AM, CR, GH, KR, MW, RU, UA,	AT, CU, GM, KZ, MX, SC, UG,	AU, CZ, GT, LA, MY, SD, US,	AZ, DE, HN, LC, MZ, SE, UZ,	DK, HR, LK, NA, SG, VC,	DM, HU, LR, NG, SK, VN,	DO, ID, LS, NI, SL, ZA,	DZ, IL, LT, NO, SM, ZM,	EC, IN, LU, NZ, SV, ZW	EE, IS, LY, OM, SY,	EG, JP, MA, PG, TJ,	ES, KE, MD, PH, TM,	FI, KG, ME, PL, TN,
:		LT, CG, KE, KZ,	LU, CI, LS, MD,	LV, CM, MW, RU,	MC, GA, MZ, TJ, 2008	MT, GN, NA, TM,	NL, GQ, SD, AP,	PL, GW, SL, EA, US 2	PT, ML, SZ, EP,	RO, MR, TZ, OA	SE, NE, UG,	SI, SN, ZM,	SK, TD, ZW,	TR, TG, AM,	BF, BW, AZ,
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT OTHER SOURCE(S): CASREACT 149:54020; MARPAT 149:54020 GI															

$$\begin{array}{c|c} & & & & \\ & & & \\ R^1- \underset{H}{N} & & & \\ & & & \\ \end{array}$$

RN CN

AB Disclosed are bisbenzamidine and bisbenzamidoxime compds. of formula I, which are useful in the treatment of human african trypanosomiasis. The compds. of formula I are useful for treating mammals infected with parasitic hemoflagellates, in particular Trypanosoma brucei gambiense and Trypanosoma brucei rhodesiense. Compds. of formula I wherein R is H and n-alkyl; R1 is H, OH, OCH3, (un)branched alkyl and cycloalkyl; n is 1-2; are claimed. Example compound II was prepared by imidation of 4,4'-(1,4-piperazinediyl)bisbenzonitrile; the resulting imidate underwent amidation with butylamine to give II. All the invention compds. were evaluated for their parasitic activity against human african trypanosomiasis. From the assay, it was determined that II exhibited an IC50 value of 0.0135 $\mu \rm M$.

IT 396106-36-8 396106-39-1 692779-50-3 1032470-98-6 1032470-99-7

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(drug candidate; preparation of bisbenzamidines and bisbenzamidoximes as parasiticides useful in the treatment of human african trypanosomiasis) 396106-36-8 CAPLUS

Benzenecarboximidamide, 4,4'-(tetrahydro-1H-1,4-diazepine-1,4(5H)-diyl)bis[N-butyl-, hydrochloride (1:2) (CA INDEX NAME)

●2 HC1

RN 396106-39-1 CAPLUS

CN Benzenecarboximidamide, 4,4'-(tetrahydro-1H-1,4-diazepine-1,4(5H)-diyl)bis[N-cyclopropyl-, hydrochloride (1:2) (CA INDEX NAME)

●2 HC1

RN 692779-50-3 CAPLUS

CN Benzenecarboximidamide, 4,4'-(tetrahydro-1H-1,4-diazepine-1,4(5H)-diyl)bis-, hydrochloride (1:2) (CA INDEX NAME)

$$\begin{array}{c|c} & \text{NH} & \text{NH} \\ \parallel & \parallel & \parallel \\ \text{H}_2\text{N-C} & \text{C-NH}_2 \end{array}$$

●2 HCl

RN 1032470-98-6 CAPLUS

CN Benzenecarboximidamide, 4,4'-(tetrahydro-1H-1,4-diazepine-1,4(5H)-diyl)bis[N-hydroxy-, hydrochloride (1:2) (CA INDEX NAME)

●2 HC1

RN 1032470-99-7 CAPLUS

CN Benzenecarboximidamide, 4,4'-(tetrahydro-1H-1,4-diazepine-1,4(5H)-diyl)bis[N-methoxy-, hydrochloride (1:2) (CA INDEX NAME)

●2 HC1

L9 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2006:333447 CAPLUS

DOCUMENT NUMBER: 144:324797

TITLE: Bisbenzamidines for the treatment of Pneumocystis

pneumonia or other infection

INVENTOR(S): Walzer, Peter D.; Cushion, Melanie T.; Mayence, Annie;

Huang, Tien Liang; Vanden Eynde, Jean Jacques

PATENT ASSIGNEE(S): University of Cincinnati, USA

SOURCE: PCT Int. Appl., 68 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PAT	PATENT NO.				KIND DATE				APPLICATION NO.						DATE			
· · · ·	WO 2006021833 WO 2006021833			A2 20060302 A3 20060713			WO 2004-IB4468						20041124					
	₩:	AE, CN, GE, LK,	AG, CO, GH, LR,	CR, GM, LS,	AM, CU, HR, LT,	CZ, HU, LU,	AU, DE, ID, LV,	DK, IL, MA,	DM, IN, MD,	DZ, IS, MG,	EC, JP, MK,	EE, KE, MN,	EG, KG, MW,	ES, KP, MX,	FI, KR, MZ,	GB, KZ, NA,	GD, LC, NI,	
	R₩:	TJ, AT, IS, CI, LS,	TM, BE, IT, CM,	TN, BG, LU, GA, MZ,	TR, CH, MC, GN, NA,	TT, CY, NL, GQ,	TZ, CZ, PL, GW, SL,	UA, DE, PT, ML,	UG, DK, RO, MR,	US, EE, SE, NE,	UZ, ES, SI, SN,	VC, FI, SK, TD,	VN, FR, TR, TG,	YU, GB, BF, BW,	ZA, GR, BJ, GH,	ZM, HU, CF, GM,	ZW IE, CG, KE,	
US 20080279917 PRIORITY APPLN. INFO.:							2008	1113		US 2007-595999 US 2003-525089P WO 2004-IB4468					20071205 P 20031125 W 20041124			

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT OTHER SOURCE(S): MARPAT 144:324797

AB A method is disclosed for combating infectious agents, e.g. Pneumocystis pneumonia, as is a method for treating a subject in need of such treatment. The method comprises administering to the subject a compound I [linker = disubstituted cyclic moiety of any ring size and may contain ≥1 heteroatom; aromatic group is 1,2-; 1,3-; or 1,4- disubstituted; R = H, C1-20 (un)branched alkyl; R' = H, C1-20 (un)branched alkyl, aromatic ring, C3-8 cycloalkyl, OH, or R and R' may form cyclic structure that can be fused to another cyclic system], or a pharmaceutically acceptable salt thereof. Pharmaceutical formulations and active compds. useful in the practice of the invention are also disclosed. Compound preparation is described.

IT 396106-36-8 396106-39-1 692779-50-3

GΙ

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (bisbenzamidines for treatment of Pneumocystis pneumonia or other infection)

RN 396106-36-8 CAPLUS

CN Benzenecarboximidamide, 4,4'-(tetrahydro-1H-1,4-diazepine-1,4(5H)-diyl)bis[N-butyl-, hydrochloride (1:2) (CA INDEX NAME)

$$\begin{array}{c|c} NH & NH & NH \\ || & & \\ N-BuNH-C & & C-NHBu-n \end{array}$$

●2 HC1

RN 396106-39-1 CAPLUS

CN Benzenecarboximidamide, 4,4'-(tetrahydro-1H-1,4-diazepine-1,4(5H)-diyl)bis[N-cyclopropyl-, hydrochloride (1:2) (CA INDEX NAME)

●2 HC1

RN 692779-50-3 CAPLUS

CN Benzenecarboximidamide, 4,4'-(tetrahydro-1H-1,4-diazepine-1,4(5H)-diyl)bis-, hydrochloride (1:2) (CA INDEX NAME)

$$\begin{array}{c} NH \\ \parallel \\ \parallel \\ N - C \\ \hline \\ N \\ \end{array} \qquad \begin{array}{c} NH \\ \parallel \\ C - NH_2 \\ \end{array}$$

●2 HC1

OS.CITING REF COUNT:

1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

REFERENCE COUNT:

2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2004:214095 CAPLUS

DOCUMENT NUMBER: 140:417313

TITLE: Evidences for the formation of bisbenzamidine-heme

complexes in cell-free systems

AUTHOR(S): Mayence, Annie; Vanden Eynde, Jean Jacques; Huang,

Tien L.

CORPORATE SOURCE: College of Pharmacy, Xavier University of Louisiana,

Division of Basic Pharmaceutical Sciences, New

Orleans, LA, 70125, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (2004),

14(7), 1625-1628

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal LANGUAGE: English

AB IR and colorimetry data suggest that bisbenzamidines connected by various rigid or flexible linkers are able to interact with heme in cell-free systems. At pH 5.0 the inhibition of formation of β -hematin could be ascertained by IR spectroscopy whereas at pH 7.0 the interaction yielded insol. complexes for which a sandwich-type structure of stoichiometry 2:1,

heme-drug, is tentatively proposed.


IT 692779-50-3

RN

RL: BSU (Biological study, unclassified); BIOL (Biological study) (complexes with heme; evidences for the formation of bisbenzamidine-heme complexes in cell-free systems)

692779-50-3 CAPLUS

CN Benzenecarboximidamide, 4,4'-(tetrahydro-1H-1,4-diazepine-1,4(5H)-diyl)bis-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

OS.CITING REF COUNT: 10 THERE ARE 10 CAPLUS RECORDS THAT CITE THIS

RECORD (10 CITINGS)

REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2003:114283 CAPLUS

DOCUMENT NUMBER: 138:280743

TITLE: Trypanocidal Activity of Conformationally Restricted

Pentamidine Congeners

AUTHOR(S): Donkor, Isaac O.; Huang, Tien L.; Tao, Bin; Rattendi,

Donna; Lane, Schennella; Vargas, Marc; Goldberg, Burt;

Bacchi, Cyrus

CORPORATE SOURCE: Department of Pharmaceutical Sciences, University of

Tennessee Health Science Center, Memphis, TN, 38163,

USA

SOURCE: Journal of Medicinal Chemistry (2003), 46(6),

1041-1048

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal LANGUAGE: English

OTHER SOURCE(S): CASREACT 138:280743

AB A series of conformationally restricted congeners of pentamidine in which

the flexible pentyl bridge of pentamidine was replaced by trans-1,2-bismethylenecyclopropyl, Ph, pyridinyl, piperazinyl,

homopiperazinyl, and piperidinyl groups were synthesized. The compds.

were evaluated for trypanocidal activity in vitro and in vivo against one drug-sensitive and three drug-resistant trypanosome isolates. The DNA binding affinity of the compds. was also studied using calf thymus DNA and

poly(dA-dT). The nature of the linker influenced the DNA binding affinity as well as the trypanocidal activity of the compds.

trans-1,2-Bis(4-amidinophenoxymethylene)cyclopropane was over 25-fold more potent than pentamidine against the drug-resistant isolate KETRI

243As-10-3, albeit with comparable DNA binding affinity.

N,N'-Bis(4-amidinophenyl) homopiperazine was the most potent trypanocide in vitro against all four trypanosome isolates studied, but

N,N'-bis(4-amidinophenyl)piperazine was the most effective agent in vivo against both drug-sensitive and drug-resistant trypanosomes.

IT 232923-88-5P 503837-66-9P 503837-67-0P 503837-68-1P 503837-69-2P 503837-70-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(trypanocidal activity of conformationally restricted pentamidine congeners)

RN 232923-88-5 CAPLUS

CN Benzenecarboximidamide, 4,4'-(tetrahydro-1H-1,4-diazepine-1,4(5H)-diyl)bis-(CA INDEX NAME)

$$\begin{array}{c|c} & NH & NH \\ \parallel & \parallel & \parallel \\ H_2N-C & & C-NH_2 \end{array}$$

RN 503837-66-9 CAPLUS

CN Benzenecarboximidamide, 4,4'-(tetrahydro-1H-1,4-diazepine-1,4(5H)-diyl)bis[N-(1-methylethyl)- (9CI) (CA INDEX NAME)

RN 503837-67-0 CAPLUS

CN Benzenecarboximidamide, 4,4'-(tetrahydro-1H-1,4-diazepine-1,4(5H)-diyl)bis[N-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

RN 503837-68-1 CAPLUS

CN Benzenecarboximidamide, 4,4'-(tetrahydro-1H-1,4-diazepine-1,4(5H)-diyl)bis[N-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)

RN 503837-69-2 CAPLUS

CN Benzenecarboximidamide, 4,4'-(tetrahydro-1H-1,4-diazepine-1,4(5H)-diyl)bis[N-butyl- (9CI) (CA INDEX NAME)

RN 503837-70-5 CAPLUS

CN Benzenecarboximidamide, 4,4'-(tetrahydro-1H-1,4-diazepine-1,4(5H)-diyl)bis[N-cyclopropyl- (9CI) (CA INDEX NAME)

OS.CITING REF COUNT: 40 THERE ARE 40 CAPLUS RECORDS THAT CITE THIS

RECORD (40 CITINGS)

REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2001:746571 CAPLUS

DOCUMENT NUMBER: 136:167355

TITLE: N, N'-Bis[4-(N-alkylamidino)phenyl]homopiperazines as

anti-Pneumocystis carinii agents

AUTHOR(S): Huang, T. L.; Tao, B.; Quarshie, Y.; Queener, S. F.;

Donkor, I. O.

CORPORATE SOURCE: College of Pharmacy, Xavier University of Louisiana,

New Orleans, LA, 70125, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (2001),

11(20), 2679-2681

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal LANGUAGE: English

OTHER SOURCE(S): CASREACT 136:167355

GI

AB Di(alkylamidinophenyl)diazepines I [R = H, HO(CH2)n (n = 2, 3), Bu, Me3C, Me2CH, cyclopropyl, cyclopentyl; R1 = H; RR1 = (CH2)3] were prepared as potential agents for the treatment of Pneumocystis carinii pneumonia (PCP). I were tested for their inhibition of Pneumocystis carinii and for their binding to DNA. I [R = cyclopropyl; R1 = H and RR1 = (CH2)3] were the most potent and caused about 70% inhibition of Pneumocystis carinii growth in a cell culture model at 1 μ M concns. There was no immediate correlation between the DNA binding properties of I and the inhibition of Pneumocystis carinii growth; I (R = cyclopentyl; R1 = H) bound most strongly to DNA but had no activity against Pneumocystis carinii in cell culture.

IT 396106-27-7 396106-32-4 503837-66-9 503837-67-0 503837-68-1 503837-69-2

503837-70-5

RL: PAC (Pharmacological activity); BIOL (Biological study)

(preparation, DNA binding properties, and inhibition of Pneumocystis carinii by di(alkylamidinophenyl)diazepines)

RN 396106-27-7 CAPLUS

CN Benzenecarboximidamide, 4,4'-(tetrahydro-1H-1,4-diazepine-1,4(5H)-diyl)bis[N-(3-hydroxypropyl)- (9CI) (CA INDEX NAME)

RN 396106-32-4 CAPLUS

CN Benzenecarboximidamide, 4,4'-(tetrahydro-1H-1,4-diazepine-1,4(5H)-diyl)bis[N-cyclopentyl- (9CI) (CA INDEX NAME)

RN 503837-66-9 CAPLUS

CN Benzenecarboximidamide, 4,4'-(tetrahydro-1H-1,4-diazepine-1,4(5H)-diyl)bis[N-(1-methylethyl)- (9CI) (CA INDEX NAME)

RN 503837-67-0 CAPLUS

CN Benzenecarboximidamide, 4,4'-(tetrahydro-1H-1,4-diazepine-1,4(5H)-diyl)bis[N-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

RN 503837-68-1 CAPLUS

CN Benzenecarboximidamide, 4,4'-(tetrahydro-1H-1,4-diazepine-1,4(5H)-diyl)bis[N-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)

RN 503837-69-2 CAPLUS

CN Benzenecarboximidamide, 4,4'-(tetrahydro-1H-1,4-diazepine-1,4(5H)-diyl)bis[N-butyl- (9CI) (CA INDEX NAME)

RN 503837-70-5 CAPLUS

CN Benzenecarboximidamide, 4,4'-(tetrahydro-1H-1,4-diazepine-1,4(5H)-diyl)bis[N-cyclopropyl- (9CI) (CA INDEX NAME)

IT 396106-34-6P

396106-35-7P

396106-36-8P

396106-37-9P 396106-40-4P 396106-38-0P

396106-39-1P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation, DNA binding properties, and inhibition of Pneumocystis carinii by di(alkylamidinophenyl)diazepines)

RN 396106-34-6 CAPLUS

CN Benzenecarboximidamide, 4,4'-(tetrahydro-1H-1,4-diazepine-1,4(5H)-diyl)bis[N-(2-hydroxyethyl)-, dihydrochloride (9CI) (CA INDEX NAME)

RN 396106-35-7 CAPLUS

CN Benzenecarboximidamide, 4,4'-(tetrahydro-1H-1,4-diazepine-1,4(5H)-diyl)bis[N-(3-hydroxypropyl)-, dihydrochloride (9CI) (CA INDEX NAME)

●2 HC1

RN 396106-36-8 CAPLUS

CN Benzenecarboximidamide, 4,4'-(tetrahydro-1H-1,4-diazepine-1,4(5H)-diyl)bis[N-butyl-, hydrochloride (1:2) (CA INDEX NAME)

●2 HC1

RN 396106-37-9 CAPLUS

CN Benzenecarboximidamide, 4,4'-(tetrahydro-1H-1,4-diazepine-1,4(5H)-diyl)bis[N-(1,1-dimethylethyl)-, dihydrochloride (9CI) (CA INDEX NAME)

●2 HC1

RN 396106-38-0 CAPLUS

CN Benzenecarboximidamide, 4,4'-(tetrahydro-1H-1,4-diazepine-1,4(5H)-

diyl)bis[N-(1-methylethyl)-, dihydrochloride (9CI) (CA INDEX NAME)

●2 HC1

RN 396106-39-1 CAPLUS

CN Benzenecarboximidamide, 4,4'-(tetrahydro-1H-1,4-diazepine-1,4(5H)-diyl)bis[N-cyclopropyl-, hydrochloride (1:2) (CA INDEX NAME)

●2 HC1

RN 396106-40-4 CAPLUS

CN Benzenecarboximidamide, 4,4'-(tetrahydro-1H-1,4-diazepine-1,4(5H)-diyl)bis[N-cyclopentyl-, dihydrochloride (9CI) (CA INDEX NAME)

●2 HC1

OS.CITING REF COUNT: 13 THERE ARE 13 CAPLUS RECORDS THAT CITE THIS

RECORD (13 CITINGS)

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

T.9 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2010 ACS on STN

1999:615756 CAPLUS ACCESSION NUMBER:

DOCUMENT NUMBER: 131:348952

TITLE: Synthesis and anti-Pneumocystis carinii activity of conformationally restricted analogues of pentamidine

AUTHOR(S): Tao, Bin; Huang, Tien L.; Zhang, Qian; Jackson,

Latasha; Queener, Sherry F.; Donkor, Isaac O.

CORPORATE SOURCE: College of Pharmacy, Xavier University of Louisiana,

New Orleans, LA, 70125, USA

SOURCE: European Journal of Medicinal Chemistry (1999), 34(6),

531-538

CODEN: EJMCA5; ISSN: 0223-5234

PUBLISHER: Editions Scientifiques et Medicales Elsevier

DOCUMENT TYPE: Journal English LANGUAGE:

GΙ

A series of conformationally restricted analogs of pentamidine in which AΒ the flexible central bridge has been replaced by trans-cyclopropyl, Ph, pyridinyl, piperazinyl or homopiperazinyl groups as conformationally restricted linkers have been synthesized. The anti-Pneumocystis carinii activity of these compds. was evaluated in a cell culture model and the DNA binding affinity was determined by thermal denaturation measurements. At 1 μ M, 5 of the analogs and pentamidine were highly effective and caused total inhibition of P. carinii growth in culture. At 0.1 μM , compds. I, II, III, and IV were more active than pentamidine with III being approx. 15-fold more effective than pentamidine. The most active compds., III and IV, showed strong binding affinities for calf thymus DNA and poly(dA-dT); however, a clear correlation between DNA binding affinity and the in vitro anti-P. carinii activity of these compds. was not observed The results suggest that the nature of the central linker influences the biol. actions of these compds.

ΤТ 232923-88-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(synthesis and anti-Pneumocystis carinii activity of conformationally restricted analogs of pentamidine)

RN 232923-88-5 CAPLUS

CN Benzenecarboximidamide, 4,4'-(tetrahydro-1H-1,4-diazepine-1,4(5H)-diyl)bis-(CA INDEX NAME)

$$\begin{array}{c|c} & NH & NH \\ \parallel & \parallel & \parallel \\ H_2N-C & & C-NH_2 \end{array}$$

OS.CITING REF COUNT: 26 THERE ARE 26 CAPLUS RECORDS THAT CITE THIS

RECORD (26 CITINGS)

REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1999:310761 CAPLUS

DOCUMENT NUMBER: 131:110891

TITLE: Novel bisbenzamidines and bisbenzimidazolines as

noncompetitive NMDA receptor antagonists

AUTHOR(S): Tao, Bin; Huang, Tien L.; Sharma, Terre A.; Reynolds,

Ian J.; Donkor, Isaac O.

CORPORATE SOURCE: College of Pharmacy, Xavier University of Louisiana,

New Orleans, LA, 70125, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (1999), 9(9),

1299-1304

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal LANGUAGE: English

AB A series of novel bisbenzamidines and bisbenzimidazolines with different linkers connecting the aromatic groups was tested in vitro for NMDA receptor antagonist activity. IC50 values for these compds. ranged from 1.2 to $>\!200~\mu\text{M}$. The bisbenzamidine with a homopiperazine ring as the central linker was the most potent NMDA receptor antagonist among all the pentamidine analogs tested so far.

IT 232923-88-5

RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (bisbenzamidines and bisbenzimidazolines as noncompetitive NMDA receptor antagonists)

RN 232923-88-5 CAPLUS

CN Benzenecarboximidamide, 4,4'-(tetrahydro-1H-1,4-diazepine-1,4(5H)-diyl)bis-(CA INDEX NAME)

$$\begin{array}{c} \text{NH} \\ \text{H}_2\text{N-C} \\ \\ \end{array} \\ \begin{array}{c} \text{NH} \\ \text{II} \\ \text{C-NH}_2 \\ \end{array}$$

OS.CITING REF COUNT: 11 THERE ARE 11 CAPLUS RECORDS THAT CITE THIS

RECORD (11 CITINGS)

REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 1 OF 2 REGISTRY COPYRIGHT 2010 ACS on STN

RN 1032815-30-7 REGISTRY

ED Entered STN: 04 Jul 2008

CN Benzenecarboximidamide, 4,4'-(tetrahydro-1H-1,4-diazepine-1,4(5H)-diyl)bis[N-methoxy- (CA INDEX NAME)

MF C21 H28 N6 O2

CI COM

SR CA

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2010 ACS on STN

RN 1032815-29-4 REGISTRY

ED Entered STN: 04 Jul 2008

CN Benzenecarboximidamide, 4,4'-(tetrahydro-1H-1,4-diazepine-1,4(5H)-diyl)bis[N-hydroxy- (CA INDEX NAME)

MF C19 H24 N6 O2

CI COM

SR CA

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT